In a RealClearHealth paper published this week, Prior Authorization: AHIP’s Commitments, Paragon Health Institute's Jackson Hammond explores recent actions taken by America’s Health Insurance Plans (AHIP) in partnership with the Trump Administration to look at reforms to when and how individuals are subjected to an insurance tool called prior authorization. First announced in July of 2025, AHIP has specifically made commitments to “streamline, simplify and reduce prior authorization,” and the paper builds out a solid framework for insurers as they consider where best to focus their efforts.
it makes sense for AHIP to commit to exploring improvements to how, when, and why prior authorization policies are used – not only for medical claims as laid out in their commitment statement but also for pharmaceutical claims, which is of interest to CMS and the Administration.
In short, the science underpinning new treatments, the economic impact of inefficient care, and the substantial population of Americans who are suffering from migraine without the ability to properly treat it, all point toward migraine as an area where reduced reliance on stringent prior authorization mechanisms would be a win for all involved.
Let's get serious.
it makes sense for AHIP to commit to exploring improvements to how, when, and why prior authorization policies are used – not only for medical claims as laid out in their commitment statement but also for pharmaceutical claims, which is of interest to CMS and the Administration.
In short, the science underpinning new treatments, the economic impact of inefficient care, and the substantial population of Americans who are suffering from migraine without the ability to properly treat it, all point toward migraine as an area where reduced reliance on stringent prior authorization mechanisms would be a win for all involved.
Let's get serious.
